ZNTL — Zentalis Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $104.33m
- -$266.75m
- $67.43m
- 35
- 57
- 20
- 30
Annual income statement for Zentalis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 67.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 119 | 165 | 227 | 300 | 259 |
| Operating Profit | -119 | -165 | -227 | -300 | -191 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -118 | -165 | -221 | -277 | -166 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -119 | -164 | -221 | -276 | -166 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -118 | -159 | -237 | -292 | -166 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -118 | -159 | -237 | -292 | -166 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.19 | -4.3 | -4.48 | -4.42 | -2.3 |